Genovis AB (publ.) (STO:GENO)

Market Cap	1.31B -2.3%
Revenue (ttm)	129.65M -1.3%
Net Income	23.50M -28.6%
EPS	0.36 -29.0%
Shares Out	66.06M
PE Ratio	55.54
Forward PE	44.75
Dividend	n/a
Ex-Dividend Date	n/a

Volume	63,543
Average Volume	111,702
Open	19.84
Previous Close	19.84
Day's Range	19.82 - 20.40
52-Week Range	15.64 - 29.80
Beta	1.77
RSI	63.67
Earnings Date	Apr 23, 2026

About Genovis AB (publ.)

Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; and GingisRE...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 36
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: GENO

Financial Performance

In 2025, Genovis AB (publ.)'s revenue was 129.65 million, a decrease of -1.27% compared to the previous year's 131.32 million. Earnings were 23.50 million, a decrease of -28.61%.